ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-final-eff-5.1.23.pdf
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1701 - 1710 လၢ 4139 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-com-pharmprogpolicynotifctn-final-4.10.23-eff-6.1.23.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP27-23 Commercial and MHCP Pharmacy Benefit Exclusion for Syfovre™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP28-23 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective June 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP29-23 Blue Cross Preferred Genetic Laboratory Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-23 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective May 1, 2023
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-23 Commercial Pharmacy Benefit Exclusion for Fluticasone-Salmeterol
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-23 Review and Update NPI Information
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP33-23 Provider Survey: Training & Development Focusing on Equity in Health Care
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP34-23 Update for New to Market Medical Drugs: Tofersen
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 12, 2023